Bowden R A
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Hematol Oncol Clin North Am. 1995 Feb;9(1):155-66.
Transfusion-associated cytomegalovirus (CMV) infections is associated with significant morbidity and mortality in immunocompromised seronegative patients. Seronegative blood products reduce the incidence of infection to less than 7%. Filtered blood may be an effective alternative to seronegative blood products for prevention of transfusion-associated CMV infection. The clinical significance of second strain CMV infection remains undefined.
输血相关巨细胞病毒(CMV)感染在免疫功能低下的血清阴性患者中与显著的发病率和死亡率相关。血清阴性血液制品可将感染发生率降低至7%以下。过滤血可能是血清阴性血液制品预防输血相关CMV感染的有效替代方法。第二株CMV感染的临床意义尚不清楚。